Mangalam Drugs revenue nearly doubles, but September-quarter loss persists

Compliance View source PDF Explain this filing

MANGALAM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.3%Reaction day

₹30.80

prior close

₹29.17

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is usedpendingvs market: pending

Pharmaceuticals peers, median of 173sector-0.2%-6.1% vs sector

On the reaction day the stock moved 6.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

-0.6

15m

-2.3

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.3pendingpending-0.2-6.1

Next day

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mangalam Drugs published its unaudited standalone and consolidated results for the September 2026 quarter and half year. Consolidated revenue was Rs 79.56 crore, up 96% from Rs 40.57 crore, while the net loss was Rs 7.21 crore versus Rs 7.35 crore. Half-year revenue rose 28% to Rs 136.79 crore and the loss narrowed to Rs 14.85 crore from Rs 21.14 crore.

Likely market impact

Stronger revenue and a narrower half-year loss help, but continued losses and negative EPS keep the near-term outlook mixed for shareholders.